Clinical Trials Actively Recruiting Patients With Lung Cancer

Get Permission

THE INFORMATION contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on patients with lung cancer. These studies highlight combinations of chemotherapy, mutation-specific treatments, stereotactic body radiation therapy, metastatic control, cancer staging, and performance status–tailored treatment. All of the studies are listed on the National Institutes of Health website at 


Study Title: A Phase I Study of Tetrathiomolybdate in Combination With Carboplatin and Pemetrexed in Chemotherapy-Naive Metastatic or Recurrent Nonsquamous Non–Small Cell Lung Cancer (NSCLC) 

Study Type: Phase I/interventional/single-group assignment 

Study Sponsor and Collaborators: University of Rochester 

Purpose: To determine the recommended phase II dose and safety of tetrathiomolybdate in combination with carboplatin and pemetrexed in chemotherapy-naive metastatic or recurrent nonsquamous NSCLC 

Primary Outcome Measures: Number of participants with adverse events as a measure of safety and tolerability [time frame: 3 years] 

Principal Investigator: David Dougherty, MD, University of Rochester; (585) 275-0394, Identifier: NCT01837329 


Study Title: A Phase IB Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant NSCLC Following Resistance to Initial Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitor 

Study Type: Phase I/interventional/single-group assignment 

Study Sponsor and Collaborators: National Cancer Institute 

Purpose: To study the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated metastatic EGFR-positive NSCLC or metastatic EGFR-positive NSCLC that has not responded to previous treatment with an initial EGFR kinase inhibitor 

Primary Outcome Measures: Feasibility of the combination therapy in T790M-positive lung cancer, measured as at least 50% of patients achieving the expected dose duration and intensity (dose expansion) [time frame: up to 12 weeks (3 courses of treatment)]; incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (dose escalation) [time frame: up to 2 years] 

Principal Investigator: Geoffrey Oxnard, MD, Dana-Farber Cancer Institute; see for contact information for each participating location Identifier: NCT02520778 


Study Title: Stereotactic Body Radiation Therapy for Inoperable Locally Advanced NSCLC 

Study Type: Phase I/interventional/parallel assignment 

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center 

Purpose: To determine whether the use of exploratory immunologic biomarkers and functional magnetic resonance imaging can serve as early predictors for response in NSCLC 

Primary Outcome Measures: Maximum tolerated dose (cohort A) [time frame: 2 years] 

Principal Investigator: Andreas Rimmer, MD, Memorial Sloan Kettering Cancer Center; (212) 639-6025 Identifier: NCT01899989 


Study Title: A Phase II Study of Lorlatinib (PF-06463922) in Advanced Anaplastic Lymphoma Kinase (ALK) and ROS Proto-Oncogene 1 (ROS1)-Rearranged NSCLC With Central Nervous System Metastasis in the Absence of Measurable Extracranial Lesions 

Study Type: Phase II/interventional/single-group assignment 

Study Sponsor and Collaborators: Massachusetts General Hospital 

Purpose: To study lorlatinib as a possible treatment for ALK-positive or ROS1-positive NSCLC 

Primary Outcome Measures: Intracranial disease control rate [time frame: 12 weeks] 

Principal Investigator: Alice T. Shaw, MD, PhD, Massachusetts General Hospital; (617) 724-4000 Identifier: NCT02927340 


Study Title: A Pilot Study Evaluating Pemetrexed in Eastern Cooperative Oncology Group (ECOG) Performance Status 3 Patients With Stage IV Nonsquamous NSCLC 

Study Type: Phase II/interventional/single-group assignment 

Study Sponsor and Collaborators: Wake Forest University Health Sciences, National Cancer Institute 

Purpose: To study how well pemetrexed disodium works in treating patients with stage IV NSCLC and an ECOG performance status of 3. Pemetrexed disodium causes fewer side effects than many chemotherapy drugs and may help treat patients with stage IV NSCLC and a lower performance status. 

Primary Outcome Measures: Change in quality of life, assessed by the European Organisation for Research and Treatment (EORTC) Quality-of-Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung Cancer 13-item [time frame: baseline to 12 weeks]; time to tumor progression [time frame: the duration of time from the start of treatment to the time of tumor progression, death, or date of last contact, assessed up to 2 years] 

Principal Investigator: Stefan Grant, MD, JD; (336) 713-5172, Identifier: NCT02426658 


Study Title: A Single-Arm, Phase II Study of Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound at the Time of Definitive Resection 

Study Type: Phase II/interventional/single-group assignment 

Study Sponsor and Collaborators: University of Kentucky 

Purpose: To study patients undergoing video-assisted thoracoscopic resection of lung cancer receiving standard therapy including lobectomy or sublobar resection and mediastinal lymph node dissection. After completion of the standard of care, intraoperative ultrasound will be used to evaluate lymph node stations for the presence of any missed lymph nodes with particular focus on lymph nodes that may appear pathologic on ultrasound evaluation. 

Primary Outcome Measures: Rate of detection of occult pathologic N2 lymph nodes [time frame: at the time of surgery] 

Principal Investigator: Angela Mahan, MD, University of Kentucky; Identifier: NCT02218242 ■

Editor’s Note: The clinical trials presented here do not represent all the trials listed on For the complete list, go to